Pioglitazone Exerts Protective Effects Against Stroke in Stroke-Prone Spontaneously Hypertensive Rats, Independently of Blood Pressure
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Purpose— Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients. However, the underlying mechanism of stroke prevention by pioglitazone is unknown. Our aim was to examine the effect of pioglitazone on hypertension-based stroke in rats. Methods— Pioglitazone (1 mg · kg −1 · d −1 ) was orally administered to stroke-prone spontaneously hypertensive rats (SHRSP) to examine the effect on incidental stroke, cerebrovascular injury, brain inflammation, oxidative stress, and vascular endothelial dysfunction induced by hypertension. Results— Treatment of SHRSP with pioglitazone for 4 weeks, without affecting blood pressure and blood glucose values, improved vascular endothelial dysfunction ( P <0.05), suppressed remodeling of the middle cerebral artery ( P <0.05) and brain microvessels ( P <0.05), and inhibited brain macrophage infiltration ( P <0.05) and the upregulation of brain monocyte chemoattractant protein-1 and tumor necrosis factor-α expression ( P <0.01). Furthermore, pioglitazone treatment significantly delayed the onset of stroke signs and death in SHRSP ( P <0.05). These beneficial effects of pioglitazone on cerebrovascular injury and stroke in SHRSP were associated with a reduction of brain and vascular superoxide via the inhibition of NADPH oxidase activity. Conclusions— Our work provides the first evidence that pioglitazone significantly protects against hypertension-induced cerebrovascular injury and stroke by improving vascular endothelial dysfunction, inhibiting brain inflammation, and reducing oxidative stress. These beneficial effects of pioglitazone were independent of blood pressure or blood sugar values. Thus, pioglitazone appears to be a potential therapeutic agent for stroke in type 2 diabetes with hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
NAD(P)H Oxidase: Role in Cardiovascular Biology and Disease
Griendling, K. K., Sorescu, D., & Ushio-Fukai, M. (2000) · Circulation Research · doi:10.1161/01.res.86.5.494 · Cited by 2,886
The role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272
Cited by
Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase
Breckwoldt, M. O., Chen, J. W., Stangenberg, L., Aikawa, E., Rodriguez, E., Qiu, S., Moskowitz, M. A., & Weissleder, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803945105 · Cited by 321
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Protecting against vascular disease in brain
Faraci, F. M. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01310.2010 · Cited by 196
MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation
Ying, W., Tseng, A., Chang, R. C.-A., Morin, A., Brehm, T., Triff, K., Nair, V., Zhuang, G., Song, H., Kanameni, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81656 · Cited by 144
The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke
Wicks, E. E., Ran, K. R., Kim, J. E., Xu, R., Lee, R. P., & Jackson, C. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897022 · Cited by 92
“demonstrated that pioglitazone, a PPARg agonist, was protective against hypertension-induced stroke by inhibiting macrophage infiltration and suppressing the expression of inflammatory cytokines CCL2 and TNF-a (174).”
BackgroundInfluentialYandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
Metadata
- Authors
- Nakamura, T., Yamamoto, E., Kataoka, K., Yamashita, T., Tokutomi, Y., Dong, Y.-F., Matsuba, S., Ogawa, H., & Kim-Mitsuyama, S.
- Venue
- Stroke
- Published
- 2007-11
- Volume
- 38
- Issue
- 11
- Pages
- 3016-3022
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2140871354
- Cited by
- 81
- References
- 3
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.